|
Activity Number:
|
473
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Wednesday, August 9, 2006 : 2:00 PM to 3:50 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #305995 |
|
Title:
|
On Dose Escalation Rules in Phase I Cancer Clinical Trials
|
|
Author(s):
|
Susan Li*+
|
|
Companies:
|
Centocor R&D, Inc.
|
|
Address:
|
965 Chesterbrook Blvd., Wayne, PA, 19087,
|
|
Keywords:
|
phase I cancer clinical trial ; dose escalation ; MTD
|
|
Abstract:
|
The primary goal of phase I cancer clinical trials is to select the appropriate dose and schedule for Phase II studies. Dose escalation rules are used in the trial to determine the maximum tolerated dose (MTD). In this presentation, a few commonly used dose escalation rules are reviewed and discussed. Rules for clinical trials of biologic treatments are recommended, they are compared with the traditional escalation rules, challenges and benefits are discussed.
|
- The address information is for the authors that have a + after their name.
- Authors who are presenting talks have a * after their name.
Back to the full JSM 2006 program |
